Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine
- Resource Type
- Authors
- Thierry H. Roels; Ben B. Monga; René-Anatole Ekpini; John N. Nkengasong; Christiane Adje; Chantal Maurice; Alan E. Greenberg; Toussaint S. Sibailly; Stefan Z. Wiktor
- Source
- AIDS (London, England). 16(4)
- Subject
- medicine.medical_specialty
Anti-HIV Agents
Immunology
Population
HIV Infections
Placebo
Gastroenterology
Zidovudine
Pregnancy
Internal medicine
Blood plasma
Drug Resistance, Viral
medicine
Immunology and Allergy
Humans
Pregnancy Complications, Infectious
education
education.field_of_study
Reverse-transcriptase inhibitor
business.industry
Viral Load
medicine.disease
CD4 Lymphocyte Count
Infectious Diseases
Cote d'Ivoire
Treatment Outcome
HIV-1
Gestation
RNA, Viral
Reverse Transcriptase Inhibitors
Female
business
Viral load
medicine.drug
- Language
- ISSN
- 0269-9370
Objective: To describe changes in HIV-1 plasma viral load (VL) and CD4 cell counts and to assess zidovudine resistance associated with a short course of oral zidovudine during late pregnancy. Methods: From April 1996 to February 1998 in Abidjan Cote dIvoire 280 HIV-1-seropositive women were randomly assigned at 36 weeks gestation to receive zidovudine (300 mg) or placebo twice a day and then one tablet every 3 h from the onset of labor until delivery. Blood samples obtained every 2 weeks until delivery then at 2 and 4 weeks and 3 or 6 months after delivery were tested from selected women based on duration of therapy for plasma VL and CD4 cell counts and samples from 20 women in the zidovudine group were tested by DNA sequencing for the presence of zidovudine resistance mutations. Results: In the zidovudine group the median reduction in plasma VL (log(10) copies/ml) was -0.48 after 2 weeks (P=0.02 versus placebo) -0.48 after 4 weeks (P=0.06) -.80 after 6 weeks (P=0.29) of treatment -0.12 at delivery (P=0.11) -0.21 at 2 weeks (P=0.83) -0.17 at 4 weeks (P=0.69) and -0.21 at 3 months (P=0.56) postpartum. Median CD4 cell counts were higher in the zidovudine than in the placebo group after 2 4 and 6 weeks of treatment (P